Photocure

Mindre end 1K følgere

PHO

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

Photocure is a medical technology company. The company specializes in photodynamic technology solutions. The solutions are used to treat diseases that cause bladder cancer and HPV. The main markets are dermatology and oncology, where the products are used by hospitals and research institutes worldwide. The company was founded in 1993 and is headquartered in Oslo, Norway.

Markedsværdi

-

Aktieomsætning

-

Omsætning

532,58 mio.

EBIT %

-0,14 %

P/E

-

Udbytteafkast, %

-

Finanskalender

7.5

2026

Delårsrapport Q1'26

25.6

2026

Generalforsamling '26

29.7

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse20.4.2026, 14.31

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Selskabsmeddelelse20.4.2026, 14.31

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Selskabsmeddelelse13.4.2026, 14.20

PHO: Financial calendar

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse13.4.2026, 06.30

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Selskabsmeddelelse13.4.2026, 06.30

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Selskabsmeddelelse16.3.2026, 16.00

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Pressemeddelelse16.3.2026, 16.00

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Selskabsmeddelelse3.3.2026, 09.35

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Pressemeddelelse3.3.2026, 09.34

Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Pressemeddelelse27.2.2026, 09.17

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Selskabsmeddelelse18.2.2026, 06.00

Photocure ASA: Results for the fourth quarter of 2025

Selskabsmeddelelse18.2.2026, 06.00

Photocure ASA: Results for the fourth quarter of 2025

Selskabsmeddelelse11.2.2026, 16.06

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Selskabsmeddelelse11.2.2026, 16.06

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Selskabsmeddelelse12.1.2026, 16.42

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Pressemeddelelse12.1.2026, 16.00

Photocure: New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Selskabsmeddelelse29.12.2025, 13.22

PHO: Financial calendar

Selskabsmeddelelse8.12.2025, 07.00

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Pressemeddelelse8.12.2025, 07.00

Photocure: The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Selskabsmeddelelse19.11.2025, 07.00

PHO: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.